Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $495.00 Price Target at Stifel Nicolaus

Key Points

• Stifel Nicolaus raised its price target for Alnylam Pharmaceuticals from $441.00 to $495.00, indicating a potential upside of 8.47% from the current price.
• Alnylam Pharmaceuticals reported $0.32 earnings per share for the last quarter, surpassing the consensus estimate by $0.86, with revenue increasing by 17.3% year-over-year.
• Insider transactions showed significant selling activity, with Director Michael W. Bonney selling 11,250 shares for a total of $5,062,500, reflecting a 40.10% decrease in ownership.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price objective increased by equities research analysts at Stifel Nicolaus from $441.00 to $495.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. Stifel Nicolaus' price target indicates a potential upside of 8.47% from the company's current price.

Other equities research analysts have also issued research reports about the company. Truist Financial started coverage on Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a "buy" rating and a $385.00 price objective for the company. Royal Bank Of Canada upped their price objective on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an "outperform" rating in a research note on Friday, September 19th. Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research report on Friday, August 1st. Finally, Jefferies Financial Group increased their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a research report on Monday, July 7th. Twenty-four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $445.35.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $456.35 on Monday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $484.21. The company has a fifty day moving average of $441.57 and a two-hundred day moving average of $339.95. The company has a market capitalization of $59.82 billion, a PE ratio of -184.76 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same period last year, the business posted ($0.13) EPS. The company's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Michael W. Bonney sold 11,250 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the completion of the sale, the director owned 16,804 shares of the company's stock, valued at $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the transaction, the executive vice president owned 54,052 shares of the company's stock, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock worth $44,160,261 over the last 90 days. Insiders own 1.20% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Atlantic Union Bankshares Corp purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at $30,000. SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at about $27,000. Bessemer Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 69 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth about $37,000. Finally, Ameritas Advisory Services LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $42,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.